Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BXS1

UPID:
IDI2_HUMAN

ALTERNATIVE NAMES:
Isopentenyl pyrophosphate isomerase 2

ALTERNATIVE UPACC:
Q9BXS1

BACKGROUND:
The enzyme Isopentenyl-diphosphate delta-isomerase 2, alternatively named Isopentenyl pyrophosphate isomerase 2, is key in the mevalonate pathway, facilitating the essential 1,3-allylic rearrangement of IPP to DMAPP. This step is critical for the synthesis of terpenoids, compounds with various biological and pharmacological properties.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Isopentenyl-diphosphate delta-isomerase 2 offers a promising avenue for drug discovery. By elucidating its role in terpenoid biosynthesis, novel therapeutic approaches targeting metabolic and possibly other related disorders could be developed.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.